tyrosine kinase


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to tyrosine kinase: Tyrosine Kinase Receptor

ty·ro·sine ki·nase

an enzyme that phosphorylates tyrosyl residues on certain proteins; many are products of viral oncogenes; a number of receptors (for example, receptors for epidermal growth factor, insulin, etc.) have this enzymatic activity; a misnomer, in that the physiologic substrate is not tyrosine but tyrosyl residues in a protein.

tyrosine kinase

n.
Any of a family of enzymes that phosphorylate tyrosine in certain proteins and play an important role in cell signaling. Mutations that affect their activity or expression can cause leukemia and other cancers.

tyrosine kinase

An enzyme intimately linked to signal transduction–ST, either as a receptor-type TK, which participates in transmembrane signaling, or as an intracellular TK, participating in ST to the nucleus; ↑ or ↓ TK activity is associated with various diseases, and alteration of TK activity at various points in its signaling pathway is of potential therapeutic interest; ↑ TK activity implicated in many CAs and other malignant and nonmalignant diseases, ASHD, psoriasis, inflammation; ↓ TK activity is linked to DM, X-linked agammaglobulinemia

tyrosine kinase

Any of a group of enzymes that influence signaling between cells, esp. as relates to cell growth and death, cellular adhesion and movement, and cellular differentiation. Abnormalities in tyrosine kinases are found in some human diseases, including chronic myeloid (myelogenous) leukemia.
See also: kinase
References in periodicals archive ?
5 XLA is caused by 600 different mutations in the Bruton tyrosine kinase (Bkt) gene.
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Summary: TEHRAN (FNA)- Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene.
Another approach has been to target the intracellular domain of these tyrosine kinases.
The development of tyrosine kinase inhibitors in gastrointestinal malignancy
10 ng/mL) and soluble fms-like tyrosine kinase 1 (sFlt1) levels were nearly threefold higher (6,356 vs.
A novel putative tyrosine kinase receptor encoded by the eph gene.
Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.
Reports from The Netherlands indicate that as certain breast cells become increasingly malignant, the activity of tyrosine kinase increases.
The company said tarloxotinib bromide, or "tarloxotinib," is its proprietary hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor exclusively licensed from the University of Auckland, New Zealand.

Full browser ?